| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 30 | 2024 | 4148 | 2.930 |
Why?
|
| Carcinoma, Squamous Cell | 32 | 2024 | 5594 | 2.370 |
Why?
|
| src-Family Kinases | 16 | 2017 | 487 | 2.230 |
Why?
|
| Protein Kinase Inhibitors | 28 | 2021 | 4965 | 2.080 |
Why?
|
| Thiazoles | 10 | 2012 | 727 | 1.910 |
Why?
|
| Papillomavirus Infections | 10 | 2024 | 999 | 1.790 |
Why?
|
| Lung Neoplasms | 33 | 2021 | 12040 | 1.680 |
Why?
|
| Pyrimidines | 19 | 2017 | 3671 | 1.570 |
Why?
|
| Pteridines | 5 | 2019 | 35 | 1.550 |
Why?
|
| Cell Cycle Proteins | 8 | 2022 | 2112 | 1.440 |
Why?
|
| Dasatinib | 13 | 2017 | 881 | 1.410 |
Why?
|
| ErbB Receptors | 17 | 2018 | 2375 | 1.340 |
Why?
|
| Oropharyngeal Neoplasms | 14 | 2024 | 1162 | 1.310 |
Why?
|
| Erlotinib Hydrochloride | 6 | 2018 | 398 | 1.270 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 18 | 2019 | 5581 | 1.240 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2019 | 2617 | 1.220 |
Why?
|
| Apoptosis | 23 | 2022 | 7755 | 1.180 |
Why?
|
| Receptor, Notch1 | 4 | 2022 | 216 | 1.120 |
Why?
|
| Antineoplastic Agents | 28 | 2023 | 14636 | 1.120 |
Why?
|
| STAT3 Transcription Factor | 7 | 2017 | 1132 | 0.970 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 1704 | 0.930 |
Why?
|
| Cell Line, Tumor | 31 | 2023 | 14873 | 0.890 |
Why?
|
| Cell Proliferation | 20 | 2022 | 7232 | 0.880 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2019 | 426 | 0.870 |
Why?
|
| Camptothecin | 5 | 2010 | 540 | 0.870 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2022 | 84 | 0.820 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2022 | 148 | 0.790 |
Why?
|
| Protein-Tyrosine Kinases | 7 | 2017 | 1837 | 0.790 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 172 | 0.720 |
Why?
|
| Receptor, EphA2 | 3 | 2013 | 138 | 0.720 |
Why?
|
| Professional-Family Relations | 1 | 2021 | 132 | 0.700 |
Why?
|
| Mutation | 16 | 2021 | 15904 | 0.700 |
Why?
|
| Goals | 1 | 2021 | 186 | 0.680 |
Why?
|
| Tumor Burden | 6 | 2018 | 2033 | 0.680 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2021 | 3924 | 0.660 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 2 | 2011 | 99 | 0.660 |
Why?
|
| Thoracic Cavity | 1 | 2018 | 10 | 0.630 |
Why?
|
| Papillomaviridae | 8 | 2024 | 636 | 0.630 |
Why?
|
| Vimentin | 1 | 2019 | 252 | 0.600 |
Why?
|
| X-Ray Microtomography | 1 | 2018 | 135 | 0.590 |
Why?
|
| Aurora Kinase A | 2 | 2018 | 209 | 0.590 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2021 | 1336 | 0.580 |
Why?
|
| Carcinoma, Small Cell | 3 | 2006 | 426 | 0.580 |
Why?
|
| LIM Domain Proteins | 1 | 2017 | 103 | 0.550 |
Why?
|
| ras Proteins | 3 | 2017 | 804 | 0.540 |
Why?
|
| Janus Kinases | 3 | 2016 | 175 | 0.540 |
Why?
|
| Humans | 101 | 2024 | 271093 | 0.540 |
Why?
|
| Terminal Care | 1 | 2021 | 466 | 0.530 |
Why?
|
| Maximum Tolerated Dose | 6 | 2016 | 1329 | 0.530 |
Why?
|
| Checkpoint Kinase 1 | 4 | 2017 | 169 | 0.520 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 738 | 0.510 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2020 | 1002 | 0.510 |
Why?
|
| Janus Kinase 2 | 2 | 2011 | 755 | 0.510 |
Why?
|
| Quinazolines | 3 | 2012 | 956 | 0.500 |
Why?
|
| Mouth Neoplasms | 4 | 2017 | 734 | 0.500 |
Why?
|
| raf Kinases | 1 | 2015 | 80 | 0.500 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2021 | 9044 | 0.500 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2015 | 84 | 0.500 |
Why?
|
| Cell Movement | 4 | 2012 | 2468 | 0.490 |
Why?
|
| Mice, Nude | 8 | 2021 | 4331 | 0.490 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 784 | 0.480 |
Why?
|
| Cisplatin | 11 | 2023 | 2499 | 0.470 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2015 | 667 | 0.470 |
Why?
|
| Cell Cycle | 6 | 2018 | 2135 | 0.470 |
Why?
|
| Cell Survival | 7 | 2016 | 3058 | 0.460 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2022 | 1903 | 0.450 |
Why?
|
| Signal Transduction | 15 | 2020 | 12044 | 0.440 |
Why?
|
| Cellular Senescence | 1 | 2016 | 389 | 0.440 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2019 | 5056 | 0.440 |
Why?
|
| Taxoids | 3 | 2016 | 1019 | 0.430 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 1536 | 0.430 |
Why?
|
| Animals | 30 | 2021 | 61554 | 0.420 |
Why?
|
| Receptor, EphA4 | 1 | 2012 | 9 | 0.420 |
Why?
|
| Ephrins | 1 | 2012 | 11 | 0.420 |
Why?
|
| Drug Interactions | 3 | 2015 | 572 | 0.410 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2018 | 417 | 0.410 |
Why?
|
| Blotting, Western | 9 | 2016 | 3570 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2020 | 16720 | 0.410 |
Why?
|
| Piperazines | 3 | 2006 | 2145 | 0.400 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2005 | 340 | 0.400 |
Why?
|
| Etoposide | 4 | 2010 | 907 | 0.400 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2023 | 5417 | 0.390 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2011 | 62 | 0.390 |
Why?
|
| Cyclin-Dependent Kinase 2 | 3 | 2017 | 252 | 0.380 |
Why?
|
| Pyrazoles | 7 | 2018 | 1551 | 0.380 |
Why?
|
| Mice | 23 | 2021 | 35477 | 0.370 |
Why?
|
| Neoplasms | 10 | 2021 | 15933 | 0.360 |
Why?
|
| STAT5 Transcription Factor | 1 | 2011 | 226 | 0.360 |
Why?
|
| DNA Repair | 2 | 2016 | 1906 | 0.350 |
Why?
|
| Ketoconazole | 1 | 2010 | 36 | 0.350 |
Why?
|
| Phosphorylation | 10 | 2019 | 4906 | 0.350 |
Why?
|
| Human papillomavirus 16 | 3 | 2022 | 255 | 0.350 |
Why?
|
| STAT Transcription Factors | 1 | 2010 | 80 | 0.350 |
Why?
|
| Enzyme Activation | 8 | 2017 | 1801 | 0.340 |
Why?
|
| Palliative Care | 1 | 2021 | 2175 | 0.330 |
Why?
|
| TYK2 Kinase | 1 | 2009 | 12 | 0.330 |
Why?
|
| Eyelashes | 1 | 2008 | 4 | 0.320 |
Why?
|
| Drug Therapy | 1 | 2009 | 205 | 0.320 |
Why?
|
| Hypertrichosis | 1 | 2008 | 7 | 0.320 |
Why?
|
| Drug Synergism | 5 | 2017 | 1355 | 0.320 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2008 | 35 | 0.310 |
Why?
|
| DNA Damage | 2 | 2017 | 1990 | 0.310 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 2 | 2021 | 291 | 0.310 |
Why?
|
| Female | 46 | 2024 | 149120 | 0.300 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 3345 | 0.300 |
Why?
|
| Biomarkers, Tumor | 11 | 2021 | 10714 | 0.300 |
Why?
|
| Deglutition Disorders | 2 | 2022 | 488 | 0.290 |
Why?
|
| Neoplasm Transplantation | 3 | 2018 | 1552 | 0.290 |
Why?
|
| Carboplatin | 4 | 2015 | 880 | 0.290 |
Why?
|
| Neoplasm Invasiveness | 6 | 2012 | 4052 | 0.280 |
Why?
|
| Disease Models, Animal | 7 | 2021 | 7320 | 0.280 |
Why?
|
| Anaphase | 2 | 2017 | 54 | 0.280 |
Why?
|
| Male | 46 | 2024 | 128484 | 0.270 |
Why?
|
| Inhibitory Concentration 50 | 5 | 2015 | 284 | 0.250 |
Why?
|
| Thiophenes | 2 | 2017 | 147 | 0.250 |
Why?
|
| Immunoprecipitation | 4 | 2013 | 590 | 0.250 |
Why?
|
| Aged | 33 | 2024 | 73550 | 0.250 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 4994 | 0.250 |
Why?
|
| Retinoblastoma Protein | 2 | 2022 | 339 | 0.240 |
Why?
|
| Middle Aged | 35 | 2024 | 90524 | 0.230 |
Why?
|
| S Phase | 3 | 2017 | 288 | 0.230 |
Why?
|
| Thyroid Neoplasms | 3 | 2021 | 1894 | 0.230 |
Why?
|
| Molecular Targeted Therapy | 3 | 2022 | 2395 | 0.230 |
Why?
|
| Drug Administration Schedule | 6 | 2010 | 3533 | 0.230 |
Why?
|
| Benzamides | 4 | 2018 | 1879 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2022 | 10400 | 0.230 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 231 | 0.230 |
Why?
|
| Epidermal Growth Factor | 1 | 2005 | 439 | 0.230 |
Why?
|
| Dinoprostone | 1 | 2004 | 219 | 0.220 |
Why?
|
| Immunologic Factors | 1 | 2007 | 670 | 0.220 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2024 | 90 | 0.220 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 1900 | 0.220 |
Why?
|
| Phenotype | 3 | 2021 | 6503 | 0.220 |
Why?
|
| Neoplasm Staging | 11 | 2021 | 14020 | 0.220 |
Why?
|
| Time Factors | 8 | 2020 | 12991 | 0.220 |
Why?
|
| Skin Neoplasms | 4 | 2021 | 4900 | 0.210 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2022 | 64 | 0.210 |
Why?
|
| Phosphatidylinositols | 1 | 2022 | 69 | 0.210 |
Why?
|
| Drug Design | 3 | 2017 | 372 | 0.210 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2022 | 86 | 0.210 |
Why?
|
| Aurora Kinase B | 1 | 2022 | 67 | 0.210 |
Why?
|
| Pleural Neoplasms | 1 | 2007 | 485 | 0.210 |
Why?
|
| Aurora Kinases | 1 | 2022 | 193 | 0.200 |
Why?
|
| Benzimidazoles | 2 | 2015 | 437 | 0.200 |
Why?
|
| Pyrazines | 2 | 2016 | 511 | 0.200 |
Why?
|
| Disease-Free Survival | 8 | 2016 | 10267 | 0.200 |
Why?
|
| Mesothelioma | 1 | 2007 | 558 | 0.200 |
Why?
|
| Lymphocyte Count | 2 | 2020 | 485 | 0.200 |
Why?
|
| RNA Interference | 2 | 2017 | 1379 | 0.200 |
Why?
|
| Immunoenzyme Techniques | 4 | 2013 | 1190 | 0.190 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2021 | 39 | 0.190 |
Why?
|
| CREB-Binding Protein | 1 | 2021 | 97 | 0.190 |
Why?
|
| Enteral Nutrition | 1 | 2024 | 341 | 0.190 |
Why?
|
| Adenocarcinoma | 4 | 2018 | 7919 | 0.190 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2021 | 97 | 0.190 |
Why?
|
| Tonsillar Neoplasms | 1 | 2021 | 81 | 0.190 |
Why?
|
| Smoking | 2 | 2016 | 2555 | 0.190 |
Why?
|
| Gene Knockdown Techniques | 3 | 2019 | 1072 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2022 | 1338 | 0.180 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 31079 | 0.180 |
Why?
|
| Homologous Recombination | 1 | 2021 | 188 | 0.180 |
Why?
|
| Gain of Function Mutation | 1 | 2021 | 133 | 0.180 |
Why?
|
| Pyrimidinones | 3 | 2017 | 319 | 0.180 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2017 | 1403 | 0.180 |
Why?
|
| Imidazoles | 2 | 2018 | 1065 | 0.180 |
Why?
|
| Enzyme Inhibitors | 3 | 2017 | 1942 | 0.170 |
Why?
|
| Adenosine Triphosphatases | 1 | 2022 | 428 | 0.170 |
Why?
|
| High-Throughput Screening Assays | 1 | 2021 | 204 | 0.170 |
Why?
|
| Phosphoproteins | 3 | 2017 | 1130 | 0.170 |
Why?
|
| Galactosyltransferases | 1 | 1999 | 10 | 0.170 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2020 | 2178 | 0.170 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 2 | 2017 | 78 | 0.170 |
Why?
|
| Treatment Outcome | 14 | 2020 | 33808 | 0.170 |
Why?
|
| Histone Acetyltransferases | 1 | 2021 | 433 | 0.170 |
Why?
|
| Immunity | 1 | 2022 | 353 | 0.170 |
Why?
|
| Survival Analysis | 7 | 2016 | 9290 | 0.170 |
Why?
|
| Immunotherapy | 3 | 2022 | 3559 | 0.160 |
Why?
|
| Patient Care Planning | 1 | 2021 | 304 | 0.160 |
Why?
|
| Orbit Evisceration | 1 | 2019 | 47 | 0.160 |
Why?
|
| Prognosis | 12 | 2024 | 22529 | 0.160 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2012 | 469 | 0.160 |
Why?
|
| Epithelial Cells | 2 | 2019 | 1877 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 6 | 2021 | 5759 | 0.160 |
Why?
|
| Lymphocytes | 2 | 2020 | 1273 | 0.160 |
Why?
|
| Integrin beta1 | 1 | 2019 | 127 | 0.160 |
Why?
|
| Disease Progression | 5 | 2020 | 6868 | 0.150 |
Why?
|
| Pyridines | 2 | 2019 | 1313 | 0.150 |
Why?
|
| Robotic Surgical Procedures | 2 | 2024 | 535 | 0.150 |
Why?
|
| Carcinoma | 2 | 2014 | 2610 | 0.150 |
Why?
|
| Streptococcus agalactiae | 1 | 1999 | 113 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2017 | 1275 | 0.150 |
Why?
|
| Drug Approval | 1 | 2019 | 176 | 0.150 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 164 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2021 | 525 | 0.150 |
Why?
|
| Gene Expression | 2 | 2019 | 3606 | 0.150 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2017 | 271 | 0.150 |
Why?
|
| Hydroxamic Acids | 2 | 2017 | 454 | 0.150 |
Why?
|
| Mice, Inbred Strains | 1 | 2018 | 556 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 52 | 0.150 |
Why?
|
| Lymphopenia | 1 | 2020 | 211 | 0.140 |
Why?
|
| Adult | 22 | 2020 | 82174 | 0.140 |
Why?
|
| Eyelid Neoplasms | 1 | 2019 | 193 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 2050 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 3657 | 0.140 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 5143 | 0.140 |
Why?
|
| Imatinib Mesylate | 3 | 2006 | 1691 | 0.140 |
Why?
|
| Anilides | 1 | 2019 | 295 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 3587 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 6258 | 0.140 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2017 | 130 | 0.140 |
Why?
|
| Pharmacogenetics | 1 | 2018 | 267 | 0.140 |
Why?
|
| Nuclear Proteins | 3 | 2017 | 3435 | 0.140 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2016 | 85 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 497 | 0.140 |
Why?
|
| Pyridinium Compounds | 1 | 2016 | 64 | 0.140 |
Why?
|
| Area Under Curve | 1 | 2018 | 730 | 0.130 |
Why?
|
| Gene Editing | 1 | 2019 | 229 | 0.130 |
Why?
|
| Quinolines | 2 | 2018 | 402 | 0.130 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2016 | 111 | 0.130 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2019 | 290 | 0.130 |
Why?
|
| Heterografts | 2 | 2015 | 738 | 0.130 |
Why?
|
| Comet Assay | 1 | 2016 | 57 | 0.130 |
Why?
|
| Papillomavirus Vaccines | 1 | 2019 | 197 | 0.130 |
Why?
|
| Streptococcal Infections | 1 | 1999 | 317 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2017 | 135 | 0.130 |
Why?
|
| Neutrophils | 1 | 2020 | 855 | 0.130 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2018 | 199 | 0.130 |
Why?
|
| CDC2 Protein Kinase | 1 | 2016 | 188 | 0.130 |
Why?
|
| Registries | 1 | 2024 | 2221 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2017 | 210 | 0.130 |
Why?
|
| Smad4 Protein | 1 | 2017 | 201 | 0.130 |
Why?
|
| Genes, ras | 2 | 2009 | 678 | 0.130 |
Why?
|
| Gentian Violet | 2 | 2005 | 23 | 0.130 |
Why?
|
| Urea | 1 | 2017 | 301 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2015 | 85 | 0.130 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 362 | 0.130 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2006 | 155 | 0.130 |
Why?
|
| Adenosine | 1 | 2017 | 292 | 0.120 |
Why?
|
| Thoracic Neoplasms | 1 | 2018 | 363 | 0.120 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 5238 | 0.120 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2015 | 123 | 0.120 |
Why?
|
| Survival Rate | 7 | 2021 | 12535 | 0.120 |
Why?
|
| Chromosomal Instability | 1 | 2015 | 228 | 0.120 |
Why?
|
| Protein Multimerization | 1 | 2015 | 231 | 0.120 |
Why?
|
| Urinary Tract Infections | 1 | 1999 | 348 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 537 | 0.120 |
Why?
|
| Tissue Array Analysis | 3 | 2013 | 757 | 0.110 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2015 | 288 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 1104 | 0.110 |
Why?
|
| Integrin beta3 | 1 | 2013 | 45 | 0.110 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 4202 | 0.110 |
Why?
|
| Cancer Survivors | 1 | 2020 | 745 | 0.110 |
Why?
|
| Bacteremia | 1 | 1999 | 721 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 561 | 0.110 |
Why?
|
| RNA, Small Interfering | 4 | 2013 | 2189 | 0.110 |
Why?
|
| Occludin | 1 | 2012 | 26 | 0.100 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 15282 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 1658 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 677 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 1095 | 0.100 |
Why?
|
| Cytokines | 3 | 2010 | 2805 | 0.100 |
Why?
|
| eIF-2 Kinase | 1 | 2013 | 166 | 0.100 |
Why?
|
| Pandemics | 1 | 2021 | 1614 | 0.100 |
Why?
|
| Retrospective Studies | 12 | 2024 | 39951 | 0.100 |
Why?
|
| Software | 2 | 2018 | 1358 | 0.100 |
Why?
|
| Transfection | 1 | 2017 | 3110 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 347 | 0.100 |
Why?
|
| Protein Kinases | 1 | 2016 | 889 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2008 | 4966 | 0.090 |
Why?
|
| Risk Assessment | 5 | 2016 | 6780 | 0.090 |
Why?
|
| Deglutition | 2 | 2022 | 187 | 0.090 |
Why?
|
| RNA, Long Noncoding | 1 | 2016 | 617 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2011 | 6343 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 1523 | 0.090 |
Why?
|
| Cell Line | 1 | 2018 | 5326 | 0.090 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2010 | 27 | 0.090 |
Why?
|
| Therapeutic Equivalency | 1 | 2009 | 49 | 0.090 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2016 | 1024 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2013 | 823 | 0.080 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 517 | 0.080 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2012 | 163 | 0.080 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2010 | 84 | 0.080 |
Why?
|
| Receptors, Cytokine | 1 | 2010 | 178 | 0.080 |
Why?
|
| Oligonucleotides | 1 | 2010 | 242 | 0.080 |
Why?
|
| Precancerous Conditions | 3 | 2010 | 1061 | 0.080 |
Why?
|
| Radiation Tolerance | 1 | 2012 | 639 | 0.080 |
Why?
|
| Glucuronosyltransferase | 1 | 2009 | 104 | 0.080 |
Why?
|
| Thymus Neoplasms | 1 | 2014 | 416 | 0.080 |
Why?
|
| Drug Antagonism | 1 | 2008 | 33 | 0.080 |
Why?
|
| Genotype | 1 | 2017 | 4249 | 0.080 |
Why?
|
| Neutropenia | 2 | 2010 | 1005 | 0.080 |
Why?
|
| Mutant Proteins | 1 | 2009 | 233 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2016 | 2124 | 0.080 |
Why?
|
| Biological Transport | 1 | 2009 | 630 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 4326 | 0.080 |
Why?
|
| Exons | 2 | 2013 | 1390 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1197 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 503 | 0.070 |
Why?
|
| Sulfones | 1 | 2008 | 145 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2010 | 822 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 3 | 2020 | 4481 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2012 | 1715 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2009 | 1023 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 5102 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2012 | 1197 | 0.070 |
Why?
|
| Biomarkers | 1 | 2018 | 5054 | 0.070 |
Why?
|
| Mesoderm | 1 | 2008 | 391 | 0.070 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 1 | 2005 | 19 | 0.070 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 1761 | 0.070 |
Why?
|
| Trypan Blue | 1 | 2005 | 15 | 0.070 |
Why?
|
| Epithelium | 1 | 2008 | 786 | 0.060 |
Why?
|
| Paxillin | 1 | 2005 | 32 | 0.060 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2005 | 27 | 0.060 |
Why?
|
| Stem Cell Factor | 1 | 2005 | 83 | 0.060 |
Why?
|
| Diarrhea | 1 | 2009 | 728 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2010 | 1032 | 0.060 |
Why?
|
| Laminin | 1 | 2005 | 208 | 0.060 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 5317 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2010 | 770 | 0.060 |
Why?
|
| Eicosanoids | 1 | 2004 | 29 | 0.060 |
Why?
|
| Cadherins | 1 | 2008 | 659 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 690 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2009 | 898 | 0.060 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 1956 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2005 | 278 | 0.060 |
Why?
|
| Pyridones | 1 | 2007 | 364 | 0.060 |
Why?
|
| G1 Phase | 1 | 2005 | 305 | 0.060 |
Why?
|
| Arachidonic Acid | 1 | 2004 | 120 | 0.060 |
Why?
|
| Denmark | 1 | 2024 | 55 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2010 | 1147 | 0.060 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2004 | 160 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 2348 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 1557 | 0.060 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2004 | 112 | 0.060 |
Why?
|
| Lung | 2 | 2021 | 3288 | 0.060 |
Why?
|
| Heart | 1 | 2010 | 1172 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 485 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2005 | 632 | 0.060 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 9039 | 0.060 |
Why?
|
| DNA Replication | 2 | 2017 | 768 | 0.060 |
Why?
|
| Adenosine Triphosphate | 1 | 2005 | 578 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2020 | 2317 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2009 | 2414 | 0.050 |
Why?
|
| Texas | 2 | 2012 | 6452 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 342 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 4006 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2017 | 617 | 0.050 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2023 | 118 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2012 | 6240 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2013 | 4105 | 0.050 |
Why?
|
| Collagen | 1 | 2005 | 723 | 0.050 |
Why?
|
| Indoles | 1 | 2008 | 1029 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 495 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 659 | 0.050 |
Why?
|
| Melanoma | 1 | 1999 | 5597 | 0.050 |
Why?
|
| Carcinogenicity Tests | 1 | 2021 | 69 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2012 | 3081 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 2198 | 0.050 |
Why?
|
| A549 Cells | 1 | 2021 | 127 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 2663 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 81 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2005 | 1990 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2020 | 4020 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2022 | 9479 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5263 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 256 | 0.050 |
Why?
|
| Young Adult | 5 | 2018 | 22293 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 1435 | 0.040 |
Why?
|
| Acetylation | 1 | 2021 | 516 | 0.040 |
Why?
|
| Protein Domains | 1 | 2021 | 317 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 3846 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 6191 | 0.040 |
Why?
|
| Bronchi | 1 | 2021 | 325 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2020 | 7645 | 0.040 |
Why?
|
| Smokers | 1 | 2020 | 154 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 1999 | 348 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 1999 | 454 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 731 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2021 | 843 | 0.040 |
Why?
|
| Tongue Neoplasms | 1 | 2020 | 253 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2013 | 1123 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 1999 | 304 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 3041 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 1586 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 2272 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2018 | 73 | 0.040 |
Why?
|
| Chemoradiotherapy | 2 | 2021 | 2028 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 528 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2024 | 13445 | 0.040 |
Why?
|
| Platinum | 1 | 2018 | 142 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 323 | 0.040 |
Why?
|
| Mutagenesis | 1 | 1999 | 511 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2021 | 670 | 0.040 |
Why?
|
| Immunoblotting | 1 | 1999 | 888 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 165 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 789 | 0.040 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 191 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 1567 | 0.040 |
Why?
|
| Glucose | 1 | 2023 | 1209 | 0.040 |
Why?
|
| Centrosome | 1 | 2017 | 106 | 0.040 |
Why?
|
| Quality of Life | 2 | 2022 | 4794 | 0.030 |
Why?
|
| CCCTC-Binding Factor | 1 | 2016 | 35 | 0.030 |
Why?
|
| Indolizines | 1 | 2016 | 47 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1999 | 690 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 158 | 0.030 |
Why?
|
| Cyclic N-Oxides | 1 | 2016 | 98 | 0.030 |
Why?
|
| Placebos | 1 | 2017 | 442 | 0.030 |
Why?
|
| Prevalence | 1 | 2024 | 3412 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2020 | 1060 | 0.030 |
Why?
|
| Purines | 1 | 2017 | 271 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2016 | 162 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3416 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2016 | 151 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 506 | 0.030 |
Why?
|
| Trastuzumab | 1 | 2018 | 743 | 0.030 |
Why?
|
| Risk Factors | 3 | 2020 | 17911 | 0.030 |
Why?
|
| Oxygenases | 1 | 2014 | 26 | 0.030 |
Why?
|
| Mucositis | 1 | 2015 | 149 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2015 | 76 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2017 | 908 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2853 | 0.030 |
Why?
|
| Tonsillectomy | 1 | 2016 | 121 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 7786 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2017 | 622 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2016 | 362 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2004 | 2923 | 0.030 |
Why?
|
| Cetuximab | 1 | 2015 | 474 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 16238 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 526 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 727 | 0.030 |
Why?
|
| Caspases | 1 | 2015 | 672 | 0.030 |
Why?
|
| Cell Division | 1 | 2016 | 2657 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2018 | 2364 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 1544 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 7900 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2012 | 317 | 0.020 |
Why?
|
| Neck Dissection | 1 | 2012 | 294 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2017 | 2585 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 5458 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 2014 | 489 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2014 | 360 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2015 | 1140 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2014 | 1825 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 557 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 566 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 1606 | 0.020 |
Why?
|
| Adolescent | 2 | 2014 | 32784 | 0.020 |
Why?
|
| Leukoplakia, Oral | 1 | 2010 | 71 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 1382 | 0.020 |
Why?
|
| Point Mutation | 1 | 2013 | 788 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 3445 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 4969 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2009 | 192 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 907 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2016 | 2770 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2007 | 206 | 0.020 |
Why?
|
| Anemia | 1 | 2010 | 727 | 0.010 |
Why?
|
| Algorithms | 1 | 2015 | 3904 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2008 | 2087 | 0.010 |
Why?
|
| Precision Medicine | 1 | 2010 | 1210 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 1456 | 0.010 |
Why?
|
| Nitriles | 1 | 2007 | 939 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2010 | 1344 | 0.010 |
Why?
|
| United States | 1 | 2019 | 15891 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2009 | 2105 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 2346 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 5692 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2010 | 2882 | 0.010 |
Why?
|
| Child | 1 | 2010 | 30596 | 0.010 |
Why?
|